Bluefin Biomedicine is focused on developing next-generation therapies aimed at enhancing the quality of life and survival rates for cancer patients. The company is dedicated to creating innovative treatment options that address the complexities of cancer, leveraging advanced scientific research to inform their therapeutic strategies. Their mission underscores a commitment to improving patient outcomes through targeted and effective interventions.

The technologies employed by Bluefin Biomedicine are centered around cutting-edge scientific advancements in cancer treatment. Their pipeline includes a range of products that utilize novel approaches to target cancer cells more effectively, potentially leading to improved efficacy and reduced side effects compared to traditional therapies. By integrating state-of-the-art research and development practices, Bluefin Biomedicine aims to bring transformative solutions to the oncology field, ultimately striving to make a significant impact on the lives of those affected by cancer.

United States

Founded in 2016, Bluefin BioMedicine is a privately held company focused on the detection of novel cancer antigens and the development of next-generation medicines for the treatment of cancer. We are using proprietary, cutting-edge protein detection methods to interrogate complex tumor specimens and discover differentially expressed cancer antigens that can be targeted with antibody therapies. Our focus is on cancers with clear unmet medical need and building a robust portfolio of therapeutic candidates that address those needs.

Bluefin Biomedicine

Company Details